Español 
Deutsch 
Français 
MSCI World Index (MSC)
NASDAQ Composite (NASDAQ)
FTSE China A50 Index (FGI)
STOXX Europe 600 (SIX)
Nikkei 300 (OSA)
NIFTY 50 (NSE)
DAX Performance Index (XETRA)
FTSE 100 (FGI)
CAC 40 (EURONEXT)
Sprint Bioscience AB (SPRINT.ST)
SEK3.66
-0.18 (-4.69%)
SE STO Healthcare Biotechnology
Address
Novum 141 57
Huddinge, AB, SE
Huddinge, AB, SE
CEO
Johan Emilsson
Website
sprintbioscience.com/sv
IPO
2014-11-07
ISIN SE0006343745
Description
Sprint Bioscience AB (publ), a pharmaceutical company, engages in the development of pharmaceutical products in the areas of cancer in Sweden. The company develops VPS34, a drug candidate for the treatment of various types of cancer by using immunotherapies; TREX1, a drug candidate for the treatment of immuno-oncology, radiotherapy and chemotherapy in the treatment of cancer. It also develops PETRA01, a drug candidate for the treatment of cancer. In addition, the company focuses on research of products for the treatment of tumor metabolism and nash. It has a research collaboration with the Experimental Drug Development Centre for expansion of metabolic dysfunction-associated steatohepatitis programme into inflammatory diseases. The company was incorporated in 2009 and is based in Huddinge, Sweden.
Market Cap & Enterprise Value
Merger & Acquisition History
No mergers or acquisitions recorded for this company.
Technical Outlook
Loading outlook…
Loading forecast...
Signal Summary
Loading…
| Indicator | 1D | 1W | 2W | 3W | 1M |
|---|
Each column is computed on that timeframe's candles (1D = daily, 1W ≈ weekly, 1M ≈ monthly), not on the same last day. ▲ bullish · ▼ bearish · — neutral. The Net row counts signals per column; hover any cell (or the indicator name) to see the exact rule behind it.
Day Score & sub-scores
Statistical fingerprint & regime detail
Conditional historical analysis
Customize analysis (advanced)
Indicative levels generated algorithmically. Not financial advice.
Risk Profile
Loading risk profile…
Price Chart
SEK3.66
-0.18 (-4.69%)
Loading historical data…
Volume Profile
Loading…
Liquidity & share structure
Average Volume
715.9K
Beta
-0.51
Float Shares
6.06M
Free Float %
5.7%
Price Performance
| 1D | 5D | 1M | 3M | 6M | YTD | 1Y | 3Y | 5Y | 10Y | Max |
|---|---|---|---|---|---|---|---|---|---|---|
| +4.96% | -1.10% | +6.19% | +65.14% | +421.74% | +141.61% | +665.96% | +408.43% | -19.64% | -93.40% | -75.98% |
Rolling Volatility
Loading…
Drawdown
Loading…
Relative Strength
Loading…
Monthly Returns Heatmap
From
To
Loading…
Annual Monthly Returns
Loading…
Daily Returns Distribution
Loading histogram data…
Revenue flow
Revenue by geography
Revenue by segment
From
To
Revenue composition
From
To
By product
By geography
Financial Statements
Select metrics from the tables below to build your comparison.
Income Statement
Balance Sheet
Cash Flow Statement
Key Metrics
Financial Ratios
Employees
Financial Growth (CAGR)
Market Data
Price Targets & DCF
Current price
3.66
Ratings Trend (MoM)
| Rating | 2026-05 | Change |
|---|---|---|
| Strong Buy | 0 | 0 |
| Buy | 0 | 0 |
| Hold | 0 | 0 |
| Sell | 0 | 0 |
| Strong Sell | 0 | 0 |
Quality scores
Altman Z-Score
20.47
Safe zone
Piotroski F-Score
5 / 9
Average
MOAT Score
1 / 10
No MOAT
Composite Rating
A-
Overall Score
4 / 5
High
DCF Score
3 / 5
Medium
ROE Score
5 / 5
High
ROA Score
5 / 5
High
D/E Score
1 / 5
Low
P/E Score
3 / 5
Medium
P/Book Score
3 / 5
Medium
Operational MOAT
✗ Below peers
-
Revenue growth Biotechnology: +1.6%+154.7% ★ Q1'26: -100.0% (vs Q1'25)
-
EPS growth Biotechnology: +29.7%+480.8% ★ Q1'26: -50.9% (vs Q1'25)
-
FCF margin FCF growth · Biotechnology: +16.2%+49.5%
-
EBIT margin Biotechnology: +0.0%+58.2% ★
-
ROIC Biotechnology: -16.1%— Q1'26: +2,807.0% (vs Q1'25)
-
Share dilution Biotechnology: -3.4%+32.6% Q1'26: +48.6% (vs Q1'25)
-
Debt / EBITDA Net debt/EBITDA · Biotechnology: 0.16×0.00× ★ Q1'26: 0.00× (vs Q1'25)
Valuation Multiples
From
To
Price Forecast (3Y)
From
To
Theoretical Return — If Invested Today
* These projections are based on analyst consensus estimates and user-defined valuation multiples. This table is for informational purposes only and does not constitute a recommendation to buy or sell any security. Past performance is not indicative of future results.
Consensus Estimates
| Metric |
Dec 2015 actual |
Dec 2016 actual |
Dec 2017 actual |
Dec 2018 actual |
Dec 2019 actual |
Dec 2020 actual |
Dec 2021 actual |
Dec 2022 actual |
Dec 2023 actual |
Dec 2024 actual |
Dec 2025 actual |
Dec 2026 1 Rev. Ana. 1 EPS Ana. |
Dec 2027 1 Rev. Ana. 1 EPS Ana. |
Dec 2028 1 Rev. Ana. |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue |
7.73M
est: 8.00M (-3.4%)
|
34.99M
est: 28.00M (+25.0%)
|
23.97M
est: 30.11M (-20.4%)
|
17.94M
est: 10.0K (+179,260.0%)
|
33.54M
est: 34.00M (-1.4%)
|
16.89M
est: 15.00M (+12.6%)
|
35.11M
est: 35.00M (+0.3%)
|
83.0K
est: 32.00M (-99.7%)
|
50.49M
est: 55.00M (-8.2%)
|
65.64M
est: 69.00M (-4.9%)
|
167.17M
est: 20.20M (+727.6%)
|
80.50M
80.50M – 80.50M
+298.5% YoY
|
147.20M
147.20M – 147.20M
+82.9% YoY
|
94.00M
94.00M – 94.00M
-36.1% YoY
|
| EBITDA |
-15.15M
est: -4.73M (-220.5%)
|
5.08M
est: -16.54M (+130.7%)
|
-10.06M
est: -17.78M (+43.4%)
|
-31.06M
est: -5.9K (-525,784.5%)
|
-19.59M
est: -20.08M (+2.5%)
|
-38.05M
est: -8.86M (-329.5%)
|
-24.49M
est: -20.67M (-18.5%)
|
-60.00M
est: -18.90M (-217.4%)
|
396.0K
est: -32.49M (+101.2%)
|
-17.32M
est: -18.84M (+8.1%)
|
98.40M
est: -5.51M (+1,884.6%)
|
-21.97M
-21.97M – -21.97M
-298.5% YoY
|
-40.18M
-40.18M – -40.18M
-82.9% YoY
|
-25.66M
-25.66M – -25.66M
+36.1% YoY
|
| EBIT |
-15.36M
est: -4.79M (-220.6%)
|
4.63M
est: -16.77M (+127.6%)
|
-10.62M
est: -18.03M (+41.1%)
|
-31.76M
est: -6.0K (-530,332.6%)
|
-20.33M
est: -20.36M (+0.1%)
|
-38.75M
est: -8.98M (-331.5%)
|
-25.08M
est: -20.96M (-19.7%)
|
-60.62M
est: -19.16M (-216.4%)
|
-51.0K
est: -32.93M (+99.8%)
|
-18.24M
est: -19.48M (+6.4%)
|
97.33M
est: -5.70M (+1,806.7%)
|
-22.73M
-22.73M – -22.73M
-298.5% YoY
|
-41.56M
-41.56M – -41.56M
-82.9% YoY
|
-26.54M
-26.54M – -26.54M
+36.1% YoY
|
| Net Income |
-15.50M
est: 119.80M (-112.9%)
|
4.54M
est: 22.71M (-80.0%)
|
-10.66M
est: 84.44M (-112.6%)
|
-22.22M
est: 353.57M (-106.3%)
|
-22.74M
est: -98.35M (+76.9%)
|
-46.23M
est: -102.41M (+54.9%)
|
-25.35M
est: -46.75M (+45.8%)
|
-60.17M
est: -40.91M (-47.1%)
|
-438.0K
est: 5.84M (-107.5%)
|
-18.28M
est: -27.78M (+34.2%)
|
91.74M
est: 9.26M (+890.6%)
|
27.78M
27.78M – 27.78M
+200.0% YoY
|
46.30M
46.30M – 46.30M
+66.7% YoY
|
—
— – —
-100.0% YoY
|
| SGA |
9.33M
est: 920.32M (-99.0%)
|
11.06M
est: 3.22B (-99.7%)
|
13.19M
est: 3.46B (-99.6%)
|
17.22M
est: 1.15M (+1,396.5%)
|
18.29M
est: 3.91B (-99.5%)
|
21.11M
est: 1.73B (-98.8%)
|
22.18M
est: 4.03B (-99.4%)
|
47.44M
est: 3.68B (-98.7%)
|
42.63M
est: 6.33B (-99.3%)
|
56.28M
est: 7.92B (-99.3%)
|
—
est: 2.32B (-100.0%)
|
9.24B
9.24B – 9.24B
+298.5% YoY
|
16.90B
16.90B – 16.90B
+82.9% YoY
|
10.79B
10.79B – 10.79B
-36.1% YoY
|
| EPS |
-1.77
est: 1.72 (-203.2%)
|
0.48
est: 0.33 (+47.6%)
|
-1.09
est: 1.21 (-190.1%)
|
-1.88
est: 5.06 (-137.1%)
|
-1.51
est: -1.41 (-7.2%)
|
-2.23
est: -1.47 (-52.0%)
|
-0.73
est: -0.67 (-9.0%)
|
-1.43
est: -0.59 (-144.1%)
|
-0.01
est: 0.08 (-107.5%)
|
-0.26
est: -0.30 (+13.3%)
|
0.99
est: 0.10 (+890.0%)
|
0.30
0.30 – 0.30
+200.0% YoY
|
0.50
0.50 – 0.50
+66.7% YoY
|
—
— – —
-100.0% YoY
|
Historical Ratings (3M)
| Date | Rating | Overall | DCF | ROE | ROA | D/E | P/E | P/B |
|---|---|---|---|---|---|---|---|---|
| 2026-05-19 | A- | 4/5 | 3/5 | 5/5 | 5/5 | 1/5 | 3/5 | 3/5 |
| 2026-05-18 | A- | 4/5 | 3/5 | 5/5 | 5/5 | 1/5 | 3/5 | 4/5 |
| 2026-05-15 | A- | 4/5 | 3/5 | 5/5 | 5/5 | 1/5 | 3/5 | 4/5 |
| 2026-05-13 | A- | 4/5 | 3/5 | 5/5 | 5/5 | 1/5 | 3/5 | 4/5 |
| 2026-05-12 | A- | 4/5 | 3/5 | 5/5 | 5/5 | 1/5 | 3/5 | 4/5 |
| 2026-05-11 | A- | 4/5 | 3/5 | 5/5 | 5/5 | 1/5 | 3/5 | 4/5 |
| 2026-05-08 | A | 4/5 | 3/5 | 5/5 | 5/5 | 1/5 | 4/5 | 4/5 |
| 2026-05-07 | A | 4/5 | 3/5 | 5/5 | 5/5 | 1/5 | 4/5 | 4/5 |
| 2026-05-06 | A | 4/5 | 3/5 | 5/5 | 5/5 | 1/5 | 4/5 | 4/5 |
| 2026-05-05 | A | 4/5 | 3/5 | 5/5 | 5/5 | 1/5 | 4/5 | 4/5 |
| 2026-05-04 | A | 4/5 | 3/5 | 5/5 | 5/5 | 1/5 | 4/5 | 4/5 |
| 2026-04-30 | A | 4/5 | 3/5 | 5/5 | 5/5 | 1/5 | 4/5 | 4/5 |
| 2026-04-29 | A | 4/5 | 3/5 | 5/5 | 5/5 | 1/5 | 4/5 | 4/5 |
| 2026-04-28 | A | 4/5 | 3/5 | 5/5 | 5/5 | 1/5 | 4/5 | 4/5 |
| 2026-04-27 | A | 4/5 | 3/5 | 5/5 | 5/5 | 1/5 | 4/5 | 4/5 |
| 2026-04-24 | A | 4/5 | 3/5 | 5/5 | 5/5 | 1/5 | 4/5 | 4/5 |
| 2026-04-23 | A | 4/5 | 3/5 | 5/5 | 5/5 | 1/5 | 4/5 | 4/5 |
| 2026-04-22 | A | 4/5 | 3/5 | 5/5 | 5/5 | 1/5 | 4/5 | 4/5 |
| 2026-04-21 | A- | 4/5 | 3/5 | 5/5 | 5/5 | 1/5 | 3/5 | 4/5 |
| 2026-04-20 | A- | 4/5 | 3/5 | 5/5 | 5/5 | 1/5 | 3/5 | 4/5 |
| 2026-04-17 | A- | 4/5 | 3/5 | 5/5 | 5/5 | 1/5 | 3/5 | 4/5 |
| 2026-04-16 | A- | 4/5 | 3/5 | 5/5 | 5/5 | 1/5 | 3/5 | 4/5 |
Owner Earnings
Owner's Earnings (history)
From
To
Owner alignment
Owner's Earnings TTM
89.84M
OE per share TTM
0.80
Owner's Yield
23.65%
Maintenance CapEx ratio
5.76%
Maint CapEx / Avg PPE
5.6%
Ownership Overview
Ownership breakdown
Ownership breakdown not available.
At a glance
Institutional holders
—
Total invested
—
Insider transactions (90d)
0
Beneficial owners (>5%)
0
Beneficial owners (>5%)
No beneficial ownership filings recorded.
Institutional Activity (13F)
Institutional ownership trend
Institutional history not available.
Top institutional holders
Top holders not available.
ETF Ownership
Top ETFs holding this stock
Held by 1 ETFs in our universe
| # | ETF | Weight | Est. AUM exposure | TER |
|---|---|---|---|---|
| 1 | iShares International Small-Cap Equity Factor ETF ISCF | 0.01% | 78.6K | 0.24% |
Insider Activity
Insider Activity — Latest Quarter
No insider activity available.
Insider buys vs sells (history)
Insider history not available.
Recent insider transactions
No recent insider transactions.
Executive team
Top executives
EBIT / Employee
3.24M
Shares Outstanding
105.52M
Executive compensation
Executive compensation (annual)
Executive compensation not available.
CEO compensation breakdown
No CEO compensation history available.
Proxy statements
Proxy statements (DEF 14A)
No proxy statements available for this company yet.
Recent SEC filings
Recent SEC filings
No SEC filings available for this company yet.
Executive team
| Name | Title | Compensation | Gender |
|---|---|---|---|
| Johan Emilsson | Chief Executive Officer | 2M | male |
| Pär Nordlund | Founder | 25.0K | — |
| Anne-Marie Wenthzel | Chief Business Officer | — | female |
| Jenni Bjornulfson | Chief Financial Officer | — | female |
| Kenth Hallberg | Founder & Director of Structural Chemistry | — | — |
| Martin Andersson | Co-Founder, Research Director & Chief Scientific Officer | — | — |
ESG Score History
No data available for this company.
Senate Trading Activity
No Senate trading activity found for this company.
House Trading Activity
No House trading activity found for this company.
Market share among peers
Peer comparison — filtered group (TTM)
Your opinion
Share your view on this stock and instantly see how the community has voted over the last 6 months.
Community Opinion for SPRINT.ST
Short-term intention
Target Price Distribution
These are community opinions and do not constitute buy or sell advice to act on. The results shown are based on aggregated opinions and are not an investment recommendation, nor do they intend to influence any investment decision.
